Long Term Safety Assessment of SER120 in Patients With Nocturia

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Serenity Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• Patients completed SPC-SER120-DB1-200901 and SPC-SER120-DB2-200902 studies

• Willing to provide consent for the study

Exclusion Criteria:

• Incontinence

• Diabetes Insipidus, Diabetes Mellitus

• CHF

• Renal Insufficiency

• Significant medical history which make participation unacceptable